Metastatic Intraocular Melanoma
6
0
0
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
33.3%
2 terminated out of 6 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma